The Restructuring of America’s Health Agencies: What RFK Jr.’s HHS Overhaul Means for Public Health
In March 2026, Health and Human Services Secretary Robert F. Kennedy Jr. launched what he called a “revolution” — a sweeping restructuring of the nation’s most critical health agencies. The plan consolidates HHS’s 28 divisions into 15, eliminates 20,000 federal health jobs, and slashes discretionary funding from $127 billion to $95 billion, a 25% reduction. NIH funding alone is targeted for an $18 billion cut. While framed as an efficiency drive, the restructuring represents the most dramatic reshaping of U.S. public health infrastructure in modern history — and the consequences are already reverberating through every corner of American healthcare.
The Architecture of Disruption
Under Kennedy’s plan, the CDC has been instructed to reduce its workforce by 20%. The FDA, NIH, and CMS have all absorbed similarly deep personnel cuts. A new entity — the Administration for a Healthy America (AHA) — has been created to consolidate functions previously distributed across multiple agencies, with Kennedy emphasizing a shift toward “healthy foods” and away from what he has characterized as an overreliance on pharmaceutical interventions.
The layoffs began on a Tuesday morning in late March, with reduction-in-force (RIF) notices issued simultaneously across agencies. Kennedy celebrated the moment on social media, declaring “The revolution begins today!” For thousands of career scientists, epidemiologists, and public health professionals, however, it was the end of careers dedicated to protecting American health. Robert Califf, former FDA commissioner, reported being “overwhelmed with messages about the firings” as the scope of the cuts became clear.
The FDA Commissioner’s Exit: A Symptom of Deeper Problems
On May 12, 2026, FDA Commissioner Dr. Marty Makary submitted his resignation after a tenure marked by controversy and eroding institutional confidence. Makary, a surgeon who rose to prominence as a Fox News commentator critical of COVID-19 public health measures, had struggled to win the trust of FDA’s career staff. Mass layoffs, abrupt leadership changes, and a series of incidents in which the agency’s scientific principles appeared subordinated to political interests created an atmosphere of institutional crisis.
President Trump acknowledged that Makary “was having some difficulty,” while noting “he’s going to go on and he’s going to do well.” But the commissioner’s departure leaves the FDA — an agency responsible for regulating roughly 80% of the U.S. food supply and the safety of all prescription drugs — without permanent leadership at a moment of unprecedented organizational turmoil. A recent poll found alarmingly low public trust in the independence of both the FDA and CDC, a finding that has direct implications for everything from vaccine uptake to drug safety compliance.
Vaccine Policy Under Siege
Perhaps no area has been more directly affected than vaccine policy. In a move without precedent, HHS terminated all 17 members of the CDC’s Advisory Committee on Immunization Practices (ACIP) and replaced them with new appointees — many of whom, according to legal challenges, “lacked expertise in immunology and vaccinology” and held “demonstrated anti-vaccine views.” The reconstituted committee then issued sweeping changes to federal vaccine recommendations without the federally mandated public and scientific review processes.
A federal judge in March 2026 blocked these changes, ruling that the vaccine policy overhaul was procedurally invalid. The ruling temporarily invalidated the January 2026 federal immunization schedule overhaul, the 13 new ACIP appointments made between June 2025 and January 2026, and all votes cast by the reconstituted committee. The American Association of Immunologists and America’s Physician Groups submitted amicus briefs supporting the legal challenge, providing scientific expertise that the judge explicitly cited in the ruling.
Meanwhile, the FDA’s chief medical and scientific officer, Dr. Vinay Prasad, issued an internal memo stating the agency would change its vaccine approval process — allegedly based on claims that COVID-19 vaccination resulted in the deaths of 10 children. Former FDA commissioners and CDC leaders published public letters warning that the country’s vaccine infrastructure was under systematic threat, with former FDA officials describing the changes as a fundamental departure from evidence-based regulatory science.
Global Health Implications
The restructuring’s effects extend far beyond America’s borders. The CDC’s global disease detection capacity — critical for identifying and containing emerging pathogens — has been significantly reduced. HIV prevention programs, infectious disease surveillance networks, and international vaccine development partnerships have all been disrupted. Organizations like AVAC have documented how the cuts are “gutting HIV prevention, infectious disease research, and vaccine development, while threatening the stability and viability of the workforce that sustains US public health and biomedical research.”
This comes at a particularly dangerous moment: the World Health Organization has declared the ongoing Ebola outbreak in the Democratic Republic of Congo an international health emergency, and antimicrobial resistance continues to rise globally. The CDC’s diminished capacity to contribute to international outbreak response could have cascading consequences for global health security.
Senate Scrutiny and Political Dynamics
On April 10, 2026, Kennedy faced a Senate inquiry before the Committee on Health, Education, Labor, and Pensions, chaired by Republican Senator Bill Cassidy of Louisiana. The hearing highlighted growing bipartisan concern about the pace and scale of the restructuring, with even GOP centrists who had supported Kennedy’s confirmation expressing alarm at the execution of his plans.
Multiple high-level vacancies across federal health agencies remain unfilled, with some nominees stalled by concerns from both parties. Kennedy has reportedly begun to moderate some of his more controversial positions — particularly around vaccine criticism — pivoting toward “less controversial topics like healthy foods,” according to the New York Times. But the institutional damage, once done, cannot easily be reversed.
What’s at Stake
The restructuring raises fundamental questions about the relationship between political leadership and scientific expertise in public health governance. Career scientists who spent decades developing expertise in specific disease areas have been dismissed without apparent consideration of how their institutional knowledge would be replaced. Regulatory capacity for drug approvals, food safety inspections, and disease surveillance has been degraded at a time when emerging threats demand more vigilance, not less.
State health departments, which depend on CDC technical guidance and funding, now face uncertainty about everything from immunization schedules to outbreak response protocols. Some states, like Oregon, have begun passing legislation to lock in federal vaccine coverage standards as of mid-2025, effectively building firewalls against further federal policy changes. This fragmentation — a patchwork of state-level responses to federal retrenchment — represents a new and troubling chapter in American public health.
Conclusion: The Long View
It is too early to measure the full impact of the HHS restructuring. Disease outbreaks may expose surveillance gaps that went unnoticed. Drug safety problems may emerge from reduced inspection capacity. Declining vaccination rates may lead to resurgent infectious diseases that were once on the brink of elimination. These are slow-moving catastrophes that unfold over years, not weeks.
What is clear today is that the institutional memory, scientific expertise, and operational capacity of America’s health agencies have sustained a blow from which recovery will be measured in decades, not months. The question is not whether public health will be affected — it is how severely, and whether the damage can be contained before it becomes irreversible.
